Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke

Stroke, Ischemic Clinical Trial

Official title:

Moderate-intensity Rosuvastatin Plus Ezetimibe Versus High-intensity Rosuvastatin for Target LDL-C Goal Achievement in Patients With Recent Ischemic Stroke: a Randomized Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03993236
• Other study ID #: ROSETTA-Stroke
• Status: Recruiting
• Phase: Phase 4
• Start date: September 9, 2019
• Est. completion date: November 12, 2020

Study information

• Verified date: February 2020
• Source: Inje University
• Contact: Keun-Sik Hong, MD., PhD.
• Phone: 82-31-910-7277
• Email: nrhks[@]paik.ac.kr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized clinical trial for the comparison of the efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin for target LDL-C goal achievement in patients with recent ischemic stroke

Description:

The purpose of this study is to compare the efficiency and safety on the target LDL-C goal achievement between rosuvastatin 10 mg plus ezetimibe 10 mg (rosuvastatin/ezetimibe 10/10 mg) once daily versus rosuvastatin 20 mg once daily in patients with recent ischemic stroke.

The target LDL-C goal achievement rate in patients with recent ischemic stroke has not been well studied. In particular, no clinical studies have been conducted comparing the efficacy and safety of low-dose rosuvastatin plus ezetimibe with high-dose rosuvastatin single agent for achieving target LDL-C levels.

In this trial, the investigators aim to compare the efficacy of the target LDL-C achievement between rosuvastatin 10 mg plus ezetimibe 10 mg (rosuvastatin/ezetimibe 10/10 mg) and rosuvastatin 20 mg in patients with recent ischemic stroke.

For this trial, more than 292 patients (584 total) per group will be enrolled.

Subjects who were satisfied with the inclusion/exclusion criteria of this trial and who agreed to participate in the clinical trial in writing were randomly assigned to a 1:1 ratio in the experimental group (the low-dose combination of rosuvastatin plus ezetimibe) and comparator group (high-dose rosuvastatin).

The duration of administration of the drug for clinical trials is 90 days (±14 days), and the efficacy and safety evaluation parameters are compared with baseline.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 584
• Est. completion date: November 12, 2020
• Est. primary completion date: November 12, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Patients with recent ischemic stroke who meet both 1) and 2) criteria below. 1) Patients with acute ischemic stroke confirmed by DWI(diffusion-weighted imaging)

This is satisfied by meeting at least one of the following two criteria:

1. Patients who sustained stroke symptoms for more than 24 hours and had acute ischemic lesions on DWI.

2. Patients with acute ischemic lesions in DWI who had improved symptoms within 24 hours.

2) Patients with ischemic stroke within 90 days.

2. Statin therapy indicated according to the recommendations of the 2014 American Heart Association/American Stroke Association guidelines.

This is accomplished by meeting at least one of the following three criteria:

1. Patients with ischemic stroke due to arteriosclerosis and LDL-C = 100 mg / dL. (Class I; Level of Evidence B)

2. Patients with ischemic stroke due to arteriosclerosis and LDL-C <100 mg / dL. (Class I; Level of Evidence C)

3. Patients who require statin therapy due to other associated atherosclerotic cardiovascular disease. (Class I; Level of Evidence A).

3. Patients without statin dose within 28 days before ischemic stroke.

4. Patients who measured baseline LDL-C levels after an ischemic stroke. This is satisfied by meeting at least one of the following two criteria:

1. Patients who had a baseline LDL-C level before the onset of a recent ischemic stroke and started statin therapy.

2. Patients hospitalized with acute ischemic stroke who had baseline LDL-C levels after initiation of statin therapy should meet both of the following conditions:

1. Patients with LDL-C levels measured within 3 days after initiation of statin therapy

2. Patients in whom randomization and administration of the study drug can be administered within 7 days after baseline LDL-C measurement.

5. Adults over 19 years.

6. Those who voluntarily agreed in writing to the trial.

Exclusion Criteria:

1. Planned vascular intervention before the end of trial

2. Significant hepatic dysfunction (Aspartate Aminotransferase or Alanine Aminotransferase >120 IU/L)

3. Allergy or contraindication to rosuvastatin or ezetimibe

4. Alcohol or drug addiction

5. Pregnancy or breast-feeding

6. Severe anemia: Hb level <10 g/dL for men and <9 g/dL for women

7. Bleeding diathesis: platelet count <100,000/µl or prothrombin time International Normalized Ratio > 1·7

8. Inability or unwillingness to comply with study-related procedures

9. Employees of the investigator or study center, with direct involvement in the current study

10. Women unwilling to continue contraception during the study period

11. Participation in other clinical trials within three-month

12. Malignancy or other serious medical conditions with a life expectancy <6 months

13. Treatment with protease inhibitors or cyclosporine

14. Patients with severe renal impairment (creatinine clearance <30 mL / min)

15. Other reasons for ineligibility judged by investigators

Related Conditions & MeSH terms

• Ischemia
• Stroke
• Stroke, Ischemic

Intervention

Drug:
• Experimental: Rosuvastatin/Ezetimibe 10
Rosuvastatin/Ezetimibe 10/10mg orally administered once daily for 90 days
• Active Comparator: Rosuvastatin 20mg
Rosuvastatin 20mg orally administered once daily for 90 days

Locations

Country	Name	City	State
Korea, Republic of	Korea University Ansan Hospital	Ansan-Si	Gyeonggi-Do
Korea, Republic of	Hallym University Medical Center	Anyang-si	Gyeonggi-Do
Korea, Republic of	Myongji Hospital	Goyang-Si	Gyeonggi-Do
Korea, Republic of	Inje University Ilsan Paik Hospital	Ilsan	Gyeonggi-Do
Korea, Republic of	Chung-Ang University Hopital	Seoul
Korea, Republic of	Ewha Womans University Seoul hospital	Seoul
Korea, Republic of	Korea University Guro Hospital	Seoul
Korea, Republic of	Kyung-Hee University Medical Center	Seoul
Korea, Republic of	Samsung Medical Center, Sungkyunkwan University School of Medicine	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Seoul St Mary's Hospital	Seoul
Korea, Republic of	Severance Hospital, Yonsei University Health System	Seoul

Sponsors (13)

Lead Sponsor	Collaborator
Keun-Sik Hong	Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Ewha Womans University Seoul hospital, Hallym University Medical Center, Inje University, Korea University, Korea University Guro Hospital, Kyunghee University Medical Center, Myongji Hospital, Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Severance Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of subjects with LDL-C decreased more than 50% at 90days (±14 days) compared to Baseline	The percentage of subjects with LDL-C decreased more than 50% at 90days (±14 days) compared to Baseline	Baseline, Visit 4(Day 90)
Secondary	Percentage of subjects with LDL-C less than 70 mg/dL at 90 days(±14 days)	Percentage of subjects with LDL-C less than 70 mg/dL at 90 days(±14 days)	Baseline, Visit 4(Day 90)
Secondary	The percentage of subjects with LDL-C decreased more than or less than 70 mg/dL at 90 days(±14 days)	The percentage of subjects with LDL-C decreased more than or less than 70 mg/dL at 90 days(±14 days)	Baseline, Visit 4(Day 90)
Secondary	The decrement of LDL-C at 90 days (±14 days) compared to baseline LDL-C (absolute difference and change)	The decrement of LDL-C at 90 days (±14 days) compared to baseline LDL-C (absolute difference and change)	Baseline, Visit 4(Day 90)
Secondary	The percentage of subjects achieved multiple lipid level (Total-C < 200mg/dL, LDL-C < 70mg/dL and triglyceride < 150mg /dL)	The percentage of subjects achieved multiple lipid level (Total-C < 200mg/dL, LDL-C < 70mg/dL and triglyceride < 150mg /dL)	Baseline, Visit 4(Day 90)
Secondary	Cardiovascular event rates including stroke (ischemic or hemorrhagic), coronary artery(myocardial infarction or coronary vascular reperfusion) and death related to vascular disease.	Cardiovascular event rates including stroke (ischemic of hemorrhagic), coronary artery(myocardial infarction or coronary vascular reperfusion) and death related to vascular disease.	Baseline to Visit 4(up to 90 days)
Secondary	Number of Death of all causes.	Number of Death of all causes.	Baseline to Visit 4(up to 90 days)
Secondary	Number of subjects with newly diagnosed diabetes.	Number of subjects with newly diagnosed diabetes.	Visit 4(Day 90)
Secondary	Fatigue scale measured by Fatigue Severity Scale.	Fatigue scale measured by Fatigue Severity Scale. (The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activity and lifestyle in patients with a variety of disorders. A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity. The Fatigue Severity Scale scores range from 9 to 63, with higher scores indicating a greater fatigue severity.)	Screening, Visit 4(Day 90)
Secondary	Incidence of rhabdomyolysis	Incidence of rhabdomyolysis	Baseline to Visit 4(up to 90 days)
Secondary	Incidence of serious liver dysfunction	Incidence of serious liver dysfunction (AST or ALT increase more than three times from baseline)	Baseline to Visit 4(up to 90 days)